Patents by Inventor Aaron J. W. Hsueh
Aaron J. W. Hsueh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10792311Abstract: Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.Type: GrantFiled: May 14, 2018Date of Patent: October 6, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Yuan Cheng, Aaron J. W. Hsueh, Yorino Sato
-
Publication number: 20180256649Abstract: Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.Type: ApplicationFiled: May 14, 2018Publication date: September 13, 2018Inventors: Yuan Cheng, Aaron J.W. Hsueh, Yorino Sato
-
Patent number: 10010565Abstract: Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.Type: GrantFiled: December 14, 2012Date of Patent: July 3, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Yuan Cheng, Aaron J. W. Hsueh, Yorino Sato
-
Publication number: 20170290890Abstract: Methods are provided for stimulating ovarian follicles in a mammal through activation of the mTor signaling pathway.Type: ApplicationFiled: September 9, 2015Publication date: October 12, 2017Inventors: Yuan Cheng, Aaron J.W. Hsueh
-
Publication number: 20170051249Abstract: Methods are provided for activating dormant ovarian primordial follicles in a mammal to promote development to preovulatory follicles.Type: ApplicationFiled: September 23, 2016Publication date: February 23, 2017Inventors: Aaron J.W. Hsueh, Jing Li
-
Publication number: 20150307571Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: July 7, 2015Publication date: October 29, 2015Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Publication number: 20150231209Abstract: Methods are provided for stimulating ovarian follicles in a mammal through disruption of the Hippo signaling pathway.Type: ApplicationFiled: September 13, 2013Publication date: August 20, 2015Inventors: Aaron J.W. Hsueh, Yuan Cheng, Masashi Deguchi, Kazuhiro Kawamura
-
Publication number: 20150025125Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: June 25, 2013Publication date: January 22, 2015Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Publication number: 20140314762Abstract: Methods are provided for stimulating ovarian preantral and antral follicles in a mammal.Type: ApplicationFiled: December 14, 2012Publication date: October 23, 2014Inventors: Yuan Cheng, Aaron J.W. Hsueh, Yorino Sato
-
Patent number: 8481686Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: GrantFiled: October 1, 2010Date of Patent: July 9, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh
-
Patent number: 8445281Abstract: Compositions and methods are provided for enhancing the survival and promoting the maturation of mammalian oocytes, zygotes and preimplantation embryos. BDNF or BDNF agonists may be administered to an individual, or to cells in vitro, to enhance cellular maturation, embryo growth and fertilization. Accordingly, compositions comprising BDNF are herein presented for use in promoting in vivo oocyte maturation as well as for use as a component in culture media for promoting preimplantation maturation of zygotes and embryos, for instance, for use with in vitro fertilization procedures and for the production of stem cells. Additionally, compounds that interfere with the binding of BDNF to its receptor may be administered to an individual to prevent oocyte maturation, thereby acting as a contraceptive. The BNDF receptor, TrkB, and BDNF also find use in the screening and design of agonists and antagonists for use in the methods of the invention.Type: GrantFiled: June 17, 2010Date of Patent: May 21, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Kazuhiro Kawamura, Aaron J. W. Hsueh, Sabine M. Mulders
-
Publication number: 20120066775Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: October 1, 2010Publication date: March 15, 2012Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Publication number: 20110052599Abstract: Compositions and methods are provided for enhancing the survival and promoting the maturation of mammalian oocytes, zygotes and preimplantation embryos. BDNF or BDNF agonists may be administered to an individual, or to cells in vitro, to enhance cellular maturation, embryo growth and fertilization. Accordingly, compositions comprising BDNF are herein presented for use in promoting in vivo oocyte maturation as well as for use as a component in culture media for promoting preimplantation maturation of zygotes and embryos, for instance, for use with in vitro fertilization procedures and for the production of stem cells. Additionally, compounds that interfere with the binding of BDNF to its receptor may be administered to an individual to prevent oocyte maturation, thereby acting as a contraceptive. The BNDF receptor, TrkB, and BDNF also find use in the screening and design of agonists and antagonists for use in the methods of the invention.Type: ApplicationFiled: June 17, 2010Publication date: March 3, 2011Inventors: Kazuhiro Kawamura, Aaron J.W. Hsueh, Sabine M. Mulders
-
Patent number: 7829330Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: GrantFiled: November 5, 2007Date of Patent: November 9, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh
-
Publication number: 20100191040Abstract: Methods are provided for activating dormant ovarian primordial follicles in a mammal to promote development to preovulatory follicles.Type: ApplicationFiled: January 25, 2010Publication date: July 29, 2010Inventors: Aaron J.W. Hsueh, Jing Li
-
Patent number: 7763462Abstract: Compositions and methods are provided for enhancing the survival and promoting the maturation of mammalian oocytes, zygotes and preimplantation embryos. BDNF or BDNF agonists may be administered to an individual, or to cells in vitro, to enhance cellular maturation, embryo growth and fertilization. Accordingly, compositions comprising BDNF are herein presented for use in promoting in vivo oocyte maturation as well as for use as a component in culture media for promoting preimplantation maturation of zygotes and embryos, for instance, for use with in vitro fertilization procedures and for the production of stem cells. Additionally, compounds that interfere with the binding of BDNF to its receptor may be administered to an individual to prevent oocyte maturation, thereby acting as a contraceptive. The BNDF receptor, TrkB, and BDNF also find use in the screening and design of agonists and antagonists for use in the methods of the invention.Type: GrantFiled: June 13, 2007Date of Patent: July 27, 2010Assignees: The Board of Trustees of the Leland Stanford Junior University, N.V. OrganonInventors: Kazuhiro Kawamura, Aaron J. W. Hsueh, Sabine M. Mulders
-
Publication number: 20090298770Abstract: High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful as therapeutic agents capable of inhibiting the action of relaxin and InsL3. The receptors and fragments thereof also find use in the screening and design of relaxin agonists and antagonists. Conditions treatable with relaxin agonists or antagonists include prevention or induction of labor, treatment of endometriosis, treatment of skin conditions such as scleroderma that require collagen or extracellular matrix remodelling. Additionally, relaxin has been implicated in the dilation of blood vessels' smooth muscle cells directly and through release of nitric oxide and atrial natriuretic peptide.Type: ApplicationFiled: April 20, 2009Publication date: December 3, 2009Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Patent number: 7531313Abstract: High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful as therapeutic agents capable of inhibiting the action of relaxin and InsL3. The receptors and fragments thereof also find use in the screening and design of relaxin agonists and antagonists. Conditions treatable with relaxin agonists or antagonists include prevention or induction of labor, treatment of endometriosis, treatment of skin conditions such as scleroderma that require collagen or extracellular matrix remodelling. Additionally, relaxin has been implicated in the dilation of blood vessels' smooth muscle cells directly and through release of nitric oxide and atrial natriuretic peptide.Type: GrantFiled: August 1, 2006Date of Patent: May 12, 2009Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh
-
Publication number: 20080145927Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: November 5, 2007Publication date: June 19, 2008Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Patent number: 7291341Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: GrantFiled: October 8, 2003Date of Patent: November 6, 2007Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Aaron J. W. Hsueh